Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637001 | 1.00 | KCNH2 (0.42) | KCNH2TLR9GBA1CNR1CNR2 | |
| SCHEMBL30015244 | 0.94 | KCNH2 (0.41) | KCNH2TLR9GBA1CNR1CNR2 | |
| SCHEMBL24161673 | 0.92 | GBA1 (0.43) | KCNH2TLR9GBA1CNR1CNR2 | |
| SCHEMBL25339096 | 0.92 | KCNH2 (0.42) | KCNH2TLR9GBA1CNR1CNR2 | |
| SCHEMBL29914108 | 0.92 | GBA1 (0.43) | KCNH2TLR9GBA1CNR1CNR2 | |
| SCHEMBL31169895 | 0.90 | KCNH2 (0.41) | KCNH2TLR9GBA1CNR1CNR2 | |
| SCHEMBL25920297 | 0.90 | KCNH2 (0.37) | KCNH2TLR9GBA1CNR1CNR2 | |
| SCHEMBL24917972 | 0.89 | KCNH2 (0.42) | KCNH2TLR9GBA1CNR1CNR2 | |
| SCHEMBL26967343 | 0.89 | TLR9 (0.51) | KCNH2TLR9GBA1SUV39H2 | |
| SCHEMBL24717244 | 0.89 | CXCR2 (0.42) | KCNH2TLR9GBA1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590105-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-RE50490-E1 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4568952-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119677726-A | KRAS inhibitors | 百时美施贵宝公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4305037-B1 | KRAS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250059179-A1 | Heterocyclic Compounds and Methods of Use | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-4305038-B1 | KRAS G12D INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-01-29 | — | — | EP | disclosed |
| EP-4472980-A2 | QUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2022251588-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| US-20220370416-A1 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS | YALE UNIVERSITY | 2022-11-24 | — | — | US | disclosed |
| US-20220363681-A1 | OXO SIX-MEMBERED CYCLOPYRIMIDINE COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. LTD. (CN) | 2022-11-17 | — | — | US | disclosed |
| WO-2022232332-A1 | 2-AMINOBENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| EP-3886991-B1 | KRAS G12C INHIBITORS | LILLY CO ELI (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022192794-A1 | KRAS G12D INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022192790-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022119748-A1 | TRICYCLIC KRAS G12C INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-06-09 | — | — | WO | disclosed |
| CN-114222743-A | Oxoaxamembered ring pyrimidine compounds, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2022047260-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370416-A1 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | KCNH2 4835/4885TLR9 4772/4885GBA1 3386/4885 |
| US-12590105-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | KCNH2 2116/4885TLR9 2864/4885GBA1 3002/4885 |
| US-20250059179-A1 | Heterocyclic Compounds and Methods of Use | KRAS, NRAS, HRAS | KCNH2 4375/4885TLR9 4400/4885GBA1 1539/4885 |
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | AURKB, CDK9, AURKA | KCNH2 3392/4885TLR9 1579/4885GBA1 3751/4885 |
| US-20220363681-A1 | OXO SIX-MEMBERED CYCLOPYRIMIDINE COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF | KRAS, NRAS, TP53 | KCNH2 3355/4885TLR9 1528/4885GBA1 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.